Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 May;104(5):2731-2736.
doi: 10.1007/s00277-025-06381-3. Epub 2025 May 24.

Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study

Luana Fianchi #  1 , Alfonso Piciocchi #  2 , Fabio Guolo  3 , Francesco Marchesi  4 , Giovanni Marsili  2 , Chiara Cattaneo  5 , Michele Gottardi  6 , Francesco Restuccia  7 , Anna Candoni  8 , Elettra Ortu La Barbera  9 , Rita Fazzi  10 , Crescenza Pasciolla  11 , Olimpia Finizio  12 , Nicola Fracchiolla  13 , Mario Delia  14 , Federica Lessi  15 , Michela Dargenio  16 , Valentina Bonuomo  17 , Maria Ilaria Del Principe  18 , Patrizia Zappasodi  19 , Marco Picardi  20 , Claudia Basilico  21 , Monica Piedimonte  22 , Paola Minetto  23 , Patrizia Chiusolo  24 , Lucia Prezioso  25 , Caterina Buquicchio  26 , Lorella Melillo  27 , Daniele Zama  28 , Francesca Farina  29 , Valentina Mancini  30 , Michela Rondoni  31 , Alessandro Busca  32 , Livio Pagano  24
Affiliations
Comparative Study

Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study

Luana Fianchi et al. Ann Hematol. 2025 May.

Abstract

A real-life study on CPX-351 and the standard arm ('7 + 3') of the CPX-351 registrative trial in adults with secondary Acute Myeloid Leukemia were compared by an unanchored Matching-adjusted indirect comparison (MAIC), in order to evaluate the efficacy and toxicity of CPX-351. Results of this study are important to confirm the role of CPX-351 in significantly improving survival and remission rates compared with '7 + 3' with a good safety profile in AML patients with high-risk features, a target group traditionally with a very poor prognosis. Moreover, this pilot analysis underlines the potentiality of the statistical method to compare studies with strong differences.

Keywords: CPX- 351; Matching-adjusted indirect comparison; Secondary acute myeloid leukemia.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Kaplan–Meier curves for overall survival (OS) and event-free survival (EFS) in the real-life CPX- 351 study (unweighted) versus its weighted estimates
See this image and copyright information in PMC

References

    1. Guolo F, Fianchi L, Minetto P, Clavio M, Gottardi M, Galimberti S, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J [Internet]. 2020 Oct 1 [cited 2024 Mar 31];10(10). Available from: https://pubmed.ncbi.nlm.nih.gov/33024084/ - PMC - PubMed
    1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood [Internet]. 2016 May 19 [cited 2024 Mar 31];127(20):2391–405. Available from: https://pubmed.ncbi.nlm.nih.gov/27069254/ - PubMed
    1. Østgård LSG, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva I, et al. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. J Clin Oncol [Internet]. 2015 Nov 1 [cited 2024 Mar 31];33(31):3641–9. Available from: https://pubmed.ncbi.nlm.nih.gov/26304885/ - PubMed
    1. Nagel G, Weber D, Fromm E, Erhardt S, Lübbert M, Fiedler W, et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol [Internet]. 2017 Dec 1 [cited 2024 Mar 31];96(12):1993–2003. Available from: https://pubmed.ncbi.nlm.nih.gov/29090343/ - PMC - PubMed
    1. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol [Internet]. 2018 Sep 10 [cited 2024 Mar 31];36(26):2684–92. Available from: https://pubmed.ncbi.nlm.nih.gov/30024784/ - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources